The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.
Clinicians and researchers teamed up to investigate how inappropriate proinflammatory mechanisms contribute to the pathogenesis of drug-refractory epilepsy.
Alison Halliday, PhD, Technology Networks | May 19, 2023 | 5 min read
Gaining a better understanding of the dynamic and reciprocal interactions between cancer cells and the tumor microenvironment is essential for improving patient diagnosis and treatment.